

# Stig Wergeland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6054409/publications.pdf>

Version: 2024-02-01

27  
papers

687  
citations

623734

14  
h-index

580821

25  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 19-22.	1.9	39
2	Association of adverse childhood experiences with the development of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 645-650.	1.9	4
3	Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. <i>Journal of Neurology</i> , 2022, 269, 5901-5909.	3.6	1
4	Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732097304.	1.0	10
5	Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. <i>Scientific Reports</i> , 2021, 11, 7174.	3.3	17
6	Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110220.	1.0	1
7	Perinatal Depression and Anxiety in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e2789-e2800.	1.1	14
8	Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102801.	2.0	13
9	A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. <i>PLoS ONE</i> , 2021, 16, e0256155.	2.5	2
10	Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. <i>Journal of Neuroimmunology</i> , 2020, 339, 577091.	2.3	18
11	Î±-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019, 25, 987-993.	3.0	16
12	1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. <i>Neurochemistry International</i> , 2018, 112, 267-277.	3.8	13
13	Neurofilament light chain predicts disease activity in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e422.	6.0	107
14	Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2018, 323, 73-77.	2.3	13
15	Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. <i>Journal of Neuroimmunology</i> , 2018, 321, 61-65.	2.3	12
16	The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. <i>Journal of Proteomics and Bioinformatics</i> , 2016, 9, 209-219.	0.4	9
17	No association of tobacco use and disease activity in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e260.	6.0	21
18	Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. <i>Neurochemistry International</i> , 2015, 83-84, 28-40.	3.8	28

#	ARTICLE	IF	CITATIONS
19	Fingolimod does not enhance cerebellar remyelination in the cuprizone model. <i>Journal of Neuroimmunology</i> , 2015, 285, 180-186.	2.3	22
20	Vitamin D status and effect of interferon- $\beta$ 21a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 280, 21-28.	2.3	19
21	Body mass index influence interferon-beta treatment response in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 288, 92-97.	2.3	56
22	Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e25.	6.0	6
23	Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 271, 60-65.	2.3	25
24	Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1833-1840.	3.0	57
25	Deep Gray Matter Demyelination Detected by Magnetization Transfer Ratio in the Cuprizone Model. <i>PLoS ONE</i> , 2013, 8, e84162.	2.5	48
26	The cuprizone model: regional heterogeneity of pathology. <i>Apmis</i> , 2012, 120, 648-657.	2.0	36
27	Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model. <i>PLoS ONE</i> , 2011, 6, e26262.	2.5	74